The 2019 Saffron vs Ritalin Study: A Mom Breaks Down the Research You Need to Read

I want to be upfront with you: I am not a pharmacologist. I'm a former pediatric OT who spent three hours one Tuesday night — long after my kids were in bed — reading a clinical trial published in the Journal of Child and Adolescent Psychopharmacology because I couldn't stop thinking about whether there was another option for my son Oliver besides the medication conversation we'd been dreading.

What I found genuinely surprised me. And I think it might surprise you too.

Before anything else: if your child is struggling, that is not a reflection of your parenting. ADHD isn't bad behavior — it's brain chemistry. Whatever path you're on right now, you're asking the right questions by being here.

What the 2019 Study Actually Was — and Why the Design Matters

The study I'm referring to is Baziar & Aqamolaei et al., published in 2019 in the Journal of Child and Adolescent Psychopharmacology. The formal title is a mouthful, but the structure is what matters: it was a randomized, double-blind, controlled trial.

Double-blind means neither the children nor the clinicians evaluating them knew who was getting what. That's the gold standard. It eliminates the placebo effect and eliminates evaluator bias in one move.

The study enrolled 54 children between the ages of 6 and 17 who had been diagnosed with ADHD. One group received saffron at 20–30mg per day. The other group received methylphenidate — the active ingredient in Ritalin — at the standard weight-adjusted dose. The trial ran for six weeks.

Fifty-four kids isn't a massive sample. But for a first double-blind RCT on this specific comparison, it clears the bar for taking the findings seriously. This was not a supplement company's marketing study. It was peer-reviewed pharmacology research.

For a deeper look at how this fits into the broader medication vs. natural support conversation, I'd recommend reading my full breakdown of saffron vs. ADHD medication — I go into more context there about what we know and what we still don't.

What They Measured — and How They Scored ADHD Symptoms

The researchers used two validated rating scales: the ADHD Rating Scale-IV (ARS) and the Clinical Global Impressions (CGI) scale. These are standard tools used in pharmaceutical trials. They're not invented for this study — they're the same instruments used to evaluate whether Ritalin, Adderall, and Concerta work.

The ARS measures both inattention and hyperactivity/impulsivity subscores separately. Parents and teachers rate frequency of specific behaviors on a 0–3 scale. The CGI measures overall severity and overall improvement from baseline, rated by the clinician.

Both groups were evaluated at baseline, at three weeks, and at the six-week endpoint.

This matters because these aren't subjective impressions — "he seems a little better." These are standardized instruments specifically designed to detect clinically meaningful change in ADHD symptoms, and they're the same tools used in trials for every major ADHD medication on the market. If you want to understand more about why ADHD symptoms show up the way they do, this breakdown of how the ADHD brain's four pathways work fills in a lot of the picture.

The Results: What the Data Actually Showed at Six Weeks

Here's the headline finding: at the six-week endpoint, there was no statistically significant difference between the saffron group and the methylphenidate group on either the ARS total score or the CGI improvement scale.

Both groups showed meaningful reductions in ADHD symptoms from baseline. Both groups showed clinically significant improvement as rated by the clinicians using CGI. The researchers described saffron's efficacy as "comparable" to methylphenidate in this trial.

I want to be careful here and use the language the researchers used: this is one six-week trial with 54 participants. "Comparable efficacy" in this context means the two groups performed similarly on these measures in this study — it does not mean saffron is a proven substitute for medication in all children, or that we should draw sweeping conclusions from a single trial.

What it does mean is that the results were significant enough to warrant serious attention. A natural compound performing comparably to a first-line ADHD medication in a double-blind RCT is not something you find every week in the literature. For context on why saffron specifically might affect ADHD symptoms at the neurological level, understanding what's happening in the understimulated ADHD brain is a good place to start.

What the Side Effect Data Showed

This is the section I read three times.

The methylphenidate group reported the side effects that parents in ADHD communities talk about constantly: decreased appetite, insomnia, and headaches were the most common. These are well-documented, expected effects of stimulant medication. They're not reasons to panic — but they're real, and they affect quality of life.

The saffron group did not show a statistically significant difference in side effects compared to methylphenidate in this trial. However — and this is important — the saffron group did not report the appetite suppression and sleep disruption that were present in the methylphenidate group. The side effect profiles were different even when overall frequency was similar.

If you're living through ADHD medication side effects with your child right now, you understand why that distinction matters. The "zombie mode" that parents describe, the afternoon crash, the child who won't eat dinner — those are quality-of-life issues that don't show up cleanly in aggregate side effect scores but are absolutely real. The 4 PM medication crash alone has upended countless family evenings.

The Study's Limitations — Stated Honestly

The researchers themselves acknowledged the limitations, and I think it's worth naming them clearly rather than glossing over them in enthusiasm.

The sample size (54 children) is small. The trial was only six weeks — we don't have long-term data from this specific comparison. The study was conducted in Iran, which means the patient population and standard-of-care context differ from the US. And methylphenidate was given at a fixed weight-adjusted dose, which may not reflect the individualized titration that happens in real clinical practice.

These are legitimate caveats. Any honest reading of this research has to include them.

At the same time: a well-designed double-blind RCT that finds comparable efficacy and a different side effect profile is meaningful preliminary evidence. It's the kind of finding that typically leads to larger trials. It changes the conversation from "saffron is just an herbal remedy" to "saffron has measurable neurological effects worth investigating seriously."

For parents who've already been through the medication merry-go-round and are looking for evidence-backed alternatives, that distinction matters enormously.

What This Means for Your Decision — And How Saphire Fits In

I want to be direct about something: this study does not tell you to stop your child's medication. It does not tell you to start saffron instead of medication. Those are decisions that involve your child's specific neurology, their specific symptoms, and their pediatrician or psychiatrist.

What this study does give you is evidence. Real, peer-reviewed, double-blind evidence that saffron affects ADHD-related neurotransmitter pathways in a measurable way — specifically dopamine, serotonin, GABA, and norepinephrine, the same four pathways that stimulant medications target. That's why the results looked similar: both interventions were working on overlapping neurological mechanisms, just through different means.

The practical question is: if a parent wants to actually try what the researchers tested, how do they do that? The dose used in this trial was 20–30mg of saffron extract daily. That's a specific, clinically relevant amount — not a sprinkle of spice on rice.

That's where Saphire Happy Chews comes in. Saphire was specifically formulated to deliver the dose range studied in this RCT, in a kid-friendly gummy format that children actually take without a fight. It's the most straightforward way I've found to replicate what the researchers tested without sourcing bulk saffron extract and doing your own dosing math.

I've written more extensively about the full landscape of this decision — including what the research says about long-term use, how saffron compares to other natural options, and what to realistically expect — in my complete guide to saffron vs. ADHD medication. If you're seriously considering this path, that's the piece to read next.

How to Bring This to Your Child's Pediatrician

Most pediatricians have not read this study. That's not a criticism — the literature is enormous and saffron for ADHD is not yet mainstream in Western clinical practice. But that means you can walk in informed.

A few things that help:

• Name the study specifically: Baziar S, Aqamolaei A, et al. J Child Adolesc Psychopharmacol. 2019.
• Lead with the design: "It was a double-blind randomized controlled trial" — that language signals you've done real research, not just read a blog post.
• Frame it as a question, not a demand: "I read about this RCT comparing saffron to methylphenidate — would you be open to discussing whether it might be worth trying alongside what we're already doing?"
• Bring your child's specific symptom picture. This study found comparable results overall, but your child's dominant challenges — inattention vs. hyperactivity vs. emotional dysregulation — matter for the conversation.

If your child is currently on medication and you're exploring whether there's a natural complement, this piece on adding natural support alongside medication has practical guidance for exactly that conversation.

And if you're earlier in the process — still figuring out what you're even dealing with — this overview of ADHD supplements for kids gives you the full landscape before you narrow in on any single option.

You are not grasping at straws by looking at this research. You are doing exactly what a good parent does: finding the best available evidence and using it to make the most informed decision you can for your specific child.